eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2010
vol. 14
 
Share:
Share:
abstract:
Review paper

Epotilony – nadzieja dla pacjentów niewrażliwych na leczenie taksanami

Aneta Rogalska
,
Agnieszka Marczak
,
Marzena Szwed
,
Arkadiusz Gajek
,
Zofia Jóźwiak

Współczesna Onkologia (2010) vol. 14; 3 (205–210)
Online publish date: 2010/06/11
View full text Get citation
 
PlumX metrics:
Nowadays commonly used drugs in the treatment of breast cancer are the taxanes. However, in many cases after their administration, there develops multidrug resistance which reduces the effectiveness of chemotherapy. Taxanes also cause numerous side effects such as neutropenia and neuropathy. Epothilones are a new group of compounds with mechanisms of action similar to taxanes, but with more potent antiproliferative activity. This review presents the chemical structure of epothilones and their mechanism of action. We also characterise several compounds that belong to epothilones: patupilone (epothilone B), ixabepilone (BMS-247550), sagopilone (ZK-EPO) and KOS-862 (epothilone D). There has been carried out extensive research on them. The main advantage of epothilones is their efficacy in cells resistant to taxanes. It seems that this is a group of compounds which in the near future may replace the taxanes in the treatment of various types of cancer.
keywords:

epothilones, taxanes, anthracyclines, microtubules, mecha­nisms of action

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.